All News
Remuzgo-Martinez et al. Serum endothelin-1 in CTD-ILD. Significantly higher levels than healthy controls. No difference between CTD-ILD and IPF. @rheumnow #ACR22 Abstr#0123 https://t.co/Jf3AumSnjt https://t.co/Xki8LEEcnV
Richard Conway RichardPAConway ( View Tweet)
de Boysson et al. Beta-blockers may prevent aortic dilation in LVV GCA (0% vs 23%). 65 patients, retrospective , and patients were on beta-blockers for other reasons, but thought-provoking @rheumnow #ACR22 Abstr#0477 https://t.co/AVmIwCk3LV https://t.co/Plv5tcN5mR
Richard Conway RichardPAConway ( View Tweet)
Auroux et al report differential micro-RNA signatures in hand OA compared to controls (15 upregulated, 4 downregulated). No difference erosive vs non-erosive hand OA. May elucidate pathophys but also ?treatment target @rheumnow #ACR22 Abstr#0023 https://t.co/Kzv8WDmHRU https://t.co/4nCuTjvR6d
Richard Conway RichardPAConway ( View Tweet)
Gisslander et al Cluster analysis in AAV in Sweden. 5 groups. 2 PR3+ groups, younger, ENT or nerve involvement - good prognosis. 2 older MPO+ groups - lung or renal involvement - worse prognosis. @rheumnow #ACR22 Abstr#0433 https://t.co/itokBTOujS https://t.co/PG6CpZvN1a
Richard Conway RichardPAConway ( View Tweet)
#abst0129 #acr22 @rheumnow analysis 6 Euro studies of active RA, PsA, axSpA &secondary failure of TNFαi showed golimumab to be effective 2nd-line Rx. GLM show improvement in Dis activity, QoL& high retention( 2/3 pts on Rx after 12mo). https://t.co/6OeKwJpqQp
Olga Petryna DrPetryna ( View Tweet)
Kirby et al @colmkirby22 . Subclinical GCA in newly diagnosed PMR. 25 patients. 20% had LVV on US - TA in all, axillary in 1. All 5 developed clinical GCA over 1 year. @rheumnow #ACR22 Abstr#0478 https://t.co/xMMjH2XCUD https://t.co/JEtwEGTEbP
Richard Conway RichardPAConway ( View Tweet)
Papo et al. EGPA. Predictors of relapse: Age at diagnosis GC dependent asthma before EGPA (HR1.57), Arthralgia(HR 1.27),myocarditis(HR1.74),peripheral neuropathy(HR 1.39) MPO-ANCA(HR1.56), baseline eosinophil count @rheumnow #ACR22 Abstr#0432 https://t.co/Yq6Eomr9z0 https://t.co/8CYOYROi72
Richard Conway RichardPAConway ( View Tweet)
Genicular nerve block for knee OA - exciting short-term symptomatic option, great Australian work on the Ignite stage. Looking forward to seeing more!
ABST1892 Shanahan et al @Flinders #ACR22 @RheumNow https://t.co/ssYoXj4wjg
David Liew drdavidliew ( View Tweet)
Ab0373 #ACR22 SpA-U
@ChristianaSiero:
42 pts w/ SpA-r uveitis, 190 attacks
Uveitis more severe: smoking, axial & peripheral involvement, BASDAI>4, HLA-B27+, female, CRP elevation, h/o bilateral ocular involvement
Less severe: shorter disease evolution, nml vit D
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Important! Abst#2054 A Novel Treatment Response Measure (TRM) for SLE Clinical Trials is being developed, an international collaboration by clinical-academics, regulatory experts, pt reps, & industry. It will impact how clinical trials will be designed. #ACRbest @rheumnow #ACR22
TheDaoIndex KDAO2011 ( View Tweet)
Be careful what you look for? Serum from 32 ACPA+ Pts and 30 ACPA neg all w #rheumatoidarthritis had multiplexed Ab- screening microarray w 1600+ antibodies. Novel Abs were identified in each group vs healthy controls. What does this mean? #ACR22 abst#0256 @RheumNow @ACRheum https://t.co/mqL8kuUkxY
Janet Pope Janetbirdope ( View Tweet)
#ACR22 @RheumNow how do you approach treatment choices for your PsA pts on TNF inhibitors after first TNFi failure?
Olga Petryna DrPetryna ( View Tweet)
Large Korean study on risk of infections in ankylosing spondylitis patients receiving biologics.
Infection incidence risk 26 events/1000 PY
Resp infection most common, 2nd zoster
Heart disease, high DA, DM, current bDMARD use = risk factors
Abs#0372 @RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR22 Abstr#1205. Are both mRNA vaccine Pfizer or Moderna equivocal in preventing breakthrough infection in fully vaccinated patients with SARDs? @zach_wallace_md showed comparable effectiveness between the two. We can promote whichever brands to our patients @RheumNow https://t.co/yhjxNE8pr2
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ab0374 #ACR22 BASDAI during pregnancy:
50 pregnant women w/ AS vs controls
AUC for BASDAI in 1st trimester: 0.74, max value for morning stiffness severity (0.9) & duration (0.8)
In 2nd and 3rd trimester: AUC for fatigue and back pain <0.5, morning stiffness remains 0.8
@RheumNow https://t.co/ZQyB37dDxX
Eric Dein ericdeinmd ( View Tweet)
Happening soon in Terrace Ballroom 2
@RheumNow #acr22 https://t.co/6FMFlPxEHc
Eric Dein ericdeinmd ( View Tweet)
Abs 0135 suggests that JAKi may successful tx for Inflammatory ocular pathology (IOP), including uveitis, epi/scleritis, & peripheral ulcerative keratitis, including after failure of cs/bDMARDs. #ACR22 @RheumNow https://t.co/9EDhtSzj1C https://t.co/0LqssF1P8H
Dr. Rachel Tate uptoTate ( View Tweet)
Early AMPLE study proteomic analysis showed 3 potential biomarkers (ANGPT1, TNFRSF10C, and GIF) for predicting CV risk/RA tx response to ABA vs ADA in Abs 0244. Possible new markers for personalized medicine? Can't wait to see more! #ACR22 @RheumNow https://t.co/QRpjJWzNYH https://t.co/6t6SDbouII
Dr. Rachel Tate uptoTate ( View Tweet)
Abs 0251 shows serum NFATc1 assoc'd w/ lipid panel abnormalities & inc CVD risk in early RA pts. I have so many questions regarding clinical use. This is compelling, especially if we can correlate changes in NFATc1 level with treatments. #ACR22 @RheumNow https://t.co/z0fU5TZAiU
Dr. Rachel Tate uptoTate ( View Tweet)
The Navajo Nation has 1 rheumatologist - equitably they need 19 since #RA is 3 times more prevalent! - Dr. J Mandal #ACR22 @rheumnow https://t.co/QcAVJzd4YY https://t.co/zMuZMtl6KC
TheDaoIndex KDAO2011 ( View Tweet)